New York, November 30
Moderna Inc is about to apply for US and European emergency authorisation for its Covid vaccine on Monday (early Tuesday as per Indian time zone) after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said.
Moderna also reported that its vaccine’s efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people. The filing sets Moderna’s product up to be the second vaccine likely to receive US emergency use authorisation this year following a shot developed by Pfizer and BioNTech which had a 95% efficacy rate.
In Berlin, study published in the journal Nature Neuroscience has stated that the Covid virus can enter brain via nose. It is still unclear where the virus enters from and how it is distributed within the brain.— Agencies